PUBLISHER: Allied Market Research | PRODUCT CODE: 1266397
PUBLISHER: Allied Market Research | PRODUCT CODE: 1266397
The overactive bladder treatment market valued for $2,426.40 million in 2021 and is estimated to reach $3,465.22 million by 2031, exhibiting a CAGR of 3.6% from 2022 to 2031.
Overactive bladder (OAB) may be defined as a condition which is characterized by a group of urinary symptoms. The condition causes a frequent and sudden urge to urinate which is difficult to control. Also, the person may feel an urge to urinate several times during the day as well as nighttime. It can also be characterized by unintentional loss of urine. Though it affects population of both genders but is more prominent in women. Its symptoms include urgent and uncontrollable need to urinate, frequent involuntary loss of urine, frequent urination, and others. These symptoms can be variable depending on the condition and the individual, which makes it difficult for the healthcare provider to diagnose the condition. Several medications are available in the market for treating the overactive bladder that can help relax the bladder and reduce symptoms of OAB.
Major factors driving the growth of overactive bladder treatment market include the rise in incidence of overactive bladder, increase in prevalence of bladder stones and bladder tumor, and increase in R&D activities in the pharmaceutical field. There is a huge rise in incidence of overactive bladder in the population around the globe. This rise is attributed to an increase in several pathological conditions causing overactive bladder. Neurological disorders such as stroke and multiple sclerosis, urinary tract infection that causes frequent and excessive urination, diabetes, and hormonal changes in women during menopause, are some of the major factors causing overactive bladder.
For instance, according to an article published by Cleveland Clinic in 2022, overactive bladder is a common condition in the U.S., and it affects up to 33 million adults, which include as many as 30% men and 40% women. This boosts the growth of the overactive bladder treatment market.In addition, conditions such as enlarged prostate, constipation and previous surgery done to treat incontinence are also some of the factors causing overactive bladder. Thus, the presence of huge number of factors causing overactive bladder increases its incidences in population all around the globe. This increases the demand for treatment medications and further propels the growth of the overactive bladder treatment market.
Furthermore, the increase in R&D activities in the pharmaceutical field is boosting the growth of the market. In recent years there has been a huge rise in research activities to develop and innovate new treatment options for various diseases. Research has been carried out to discover more about the pathology of the overactive bladder and its causes. Based on detail study, drugs and molecules has been developed by the scientist to target symptoms and thus offer new entities for treatment of the condition. This is anticipated to boost the market.
In addition, investments have been made by the key market players to establish advanced manufacturing techniques for development of medication. This makes it possible for the key players to offer high quality medications to the customers, which increases its efficacy and positive results in the patient. This further raises its demand for the treatment of overactive bladder, and thus boosts the market growth. Also, key market players are shifting their focus towards emerging countries which are anticipated to expand the market during the forecast period. Investments in emerging countries will offer lucrative opportunities for the market growth owing to the increasing healthcare spending, presence of favorable government facilities, and presence of raw materials in abundance in this region.
In addition, increasing healthcare expenditure and developing healthcare facilities in regions such as Asia-Pacific, is anticipated to boost the overactive bladder market during the forecast period.Although various key factors are driving the growth of the market, the presence of few factors such as lack of awareness about overactive bladder and some side effects associated with the medications is providing hindrance to the growth of the market. There is a very low awareness about the condition among the population in underdeveloped countries. People here are unaware about the condition and also its available treatment options. In addition, the presence of alternate treatment options such as pelvic floor physical therapy and surgery is also causing hindrance to the market growth.
The overactive bladder treatment market is segmented by drug class, disease type, distribution channel and region. By drug class, the market is categorized into anti-cholinergic drugs, beta-3 adrenergic drugs, Botox, and others. On the basis of disease type, the market is segregated into idiopathic overactive bladder and neurogenic overactive bladder. On the basis of distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies and online providers.
Region wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).Major Key players that operate in the overactive bladder treatment market are AbbVie Inc., Alembic Pharmaceuticals Limited, Astellas Pharma Inc., Cipla Ltd., Dr. Reddy's Laboratories Ltd., Lupin, Pfizer Inc., Sumitomo Pharma Co., Ltd, Inc., Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Limited.